Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| TREVI THERAPEUTICS | 6 | - | +4,68 % | ||
| TYRA BIOSCIENCES | 5 | 9 | +2,17 % | ||
| BIONTECH | 4 | 13 | +1,67 % | ||
| GILEAD SCIENCES | 4 | 5 | -0,60 % | ||
| SPYRE THERAPEUTICS | 4 | 3 | +4,20 % | ||
| KURA ONCOLOGY | 4 | 2 | +8,42 % | ||
| MODERNA | 3 | 16 | +0,39 % | ||
| ARCELLX | 3 | 2 | -0,06 % | ||
| ALLOGENE THERAPEUTICS | 2 | 6 | +0,85 % | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2 | 3 | +5,65 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21:10 | Zymeworks Inc.: Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform | 71 | GlobeNewswire (Europe) | Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability... ► Artikel lesen | |
| 21:06 | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | 97 | Business Wire | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| 21:02 | Moderna, Inc.: Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting | 124 | ACCESS Newswire | The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS>1%)... ► Artikel lesen | |
| 20:18 | Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst | 3 | Benzinga.com | ||
| 19:26 | Jim Cramer on Gilead Sciences: "I'd Hold On to It" | 5 | Insider Monkey | ||
| 19:10 | Can Myqorzo Drive Growth for Cytokinetics Amid Competition? | 4 | Zacks | ||
| 19:10 | DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock? | 2 | Zacks | ||
| 17:22 | Genmab schließt Kapitalherabsetzung um 1,9 Millionen Aktien ab | 5 | Investing.com Deutsch | ||
| 17:18 | Genmab completes share capital reduction of 1.9 million shares | 2 | Investing.com | ||
| 17:08 | XETR DELETION OF INSTRUMENTS FROM XETRA - 17.04.2026 -2- | 359 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 17.04.2026.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.ISIN Name US5719032022 Marriott International... ► Artikel lesen | |
| 17:06 | XETR DELETION OF INSTRUMENTS FROM XETRA - 17.04.2026 -1- | 344 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 17.04.2026.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.ISIN Name US0028962076 Abercrombie &... ► Artikel lesen | |
| 17:00 | Genmab A/S Share Capital Reduction | 110 | GlobeNewswire (Europe) | Company Announcement COPENHAGEN, Denmark; April 17, 2026 - Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital with... ► Artikel lesen | |
| 16:54 | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | 1 | Investing.com | ||
| 16:54 | Weekly Buzz: FDA Okays Travere Therapeutics, Royal Philips; Rejects Replimune; American Industrial Partners Snaps Up Avanos Medical; PDS Biotechnology, Hoth Therapeutics, Spyre Therapeutics, Paces Trials | 348 | AFX News | INDIANAPOLIS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections, collaborations, acquisitions, and positive... ► Artikel lesen | |
| 16:42 | Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results | 2 | Benzinga.com | ||
| 16:30 | EXKLUSIV zu Curevac: Was Insider vor dem Wochenende bereits wissen - Was das für Ihr Depot bedeutet | Hebelschein-Spekulant | |||
| 16:26 | Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability | 7 | Insider Monkey | ||
| 16:26 | Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision | 6 | Insider Monkey | ||
| 16:26 | Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus | 4 | Insider Monkey | ||
| 16:26 | Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions | 1 | Insider Monkey |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.